Background. Evidence supporting the role of xanthine oxidase in myocardial reperfusion injury is based on studies with pharmacological interventions used to inhibit enzyme function. Controversy exists, however, regarding the true role of xanthine oxidase in reperfusion injury. This study was performed to determine whether xanthine oxidase inhibition limits myocardial injury due to coronary artery occlusion and reperfusion. Methods and Results. Anesthetized dogs underwent coronary artery occlusion (90 minutes) and reperfusion (6 hours). Oxypurinol (28 mg/kg) or amfiutizole (30 mg/kg), chemically unrelated inhibitors of xanthine oxidase, or vehicle was infused intravenously 15 minutes before and 3 hours after reperfusion. Regional myocardial blood flow was determined with radiolabeled microspheres. Infarct size was determined with the tetrazolium method. Myocardial infarct size (percent of risk region) was less in oxypurinol-treated dogs, 32±16%, compared with that of the control group, 46±15%. Infarct size for the amflutizole-treated dogs, 40±21%, was not significantly different from that of the control group. There were no differences in rate-pressure product or collateral blood flow to account for differences in infarct size. Uric acid concentration in the coronary venous plasma increased after reperfusion in the dogs treated with vehicle but not in the drug-treated dogs. Xanthine oxidase inhibition was demonstrated in each of the drug treatment groups, but only oxypurinol limited the extent of myocardial injury.
Conclusions. Previously reported cardioprotective effects of allopurinol, noted to occur only when the drug was administered chronically, may be related to a property of oxypurinol, a major metabolite of allopurinol. The beneficial effect of oxypurinol is unrelated to inhibition of superoxide formation during xanthine oxidase-catalyzed oxidation of xanthine and hypoxanthine. (Circulation 1991; 83:995-1005) A tivated species of oxygen generated by the enzyme xanthine oxidase have been postulated to cause cellular injury during reperfusion of ischemic tissue.' Treatment with either oxygen radical scavengers or allopurinol, an inhibitor of xanthine oxidase, has attenuated the tissue damage caused by transient ischemia in the kidney,2 intestine,3,4 and skeletal muscle. 5 The role of xanthine oxidase in the pathogenesis of ischemic myocardial injury is controversial because the effects of xanthine oxidase inhibitors on canine myocardial infarction have been variable. [6] [7] [8] [9] [10] This study was performed to compare the effects of two chemically unrelated inhibitors of xanthine oxidase, oxypurinol and amflutizole, in a canine preparation of regional myocardial ischemia and reperfusion.
Methods
Protocol 1 Surgical preparation. Detailed methods have been published previously." Male mongrel dogs (12) (13) (14) (15) (16) (17) kg) were anesthetized with Dial-urethane (0.6 mi/kg i.v.) and were ventilated with room air. A left thoracotomy was performed, and the proximal left circumflex coronary artery was isolated and instrumented with an electromagnetic flow probe. Mass.), labeled with cesium-141 or ruthenium-103. The microspheres were prepared for administration by sonication in an ultrasonic bath and agitation with a vortex mixer. An aliquot of 1-2 million microspheres was diluted in 10 ml saline (37°C) and infused into the left atrial appendage during 30 seconds, followed by two flushes with 10 ml saline. Dual reference blood samples were withdrawn simultaneously from one femoral and one carotid artery at 3.50 ml/min. Microspheres were injected 70 minutes after coronary artery occlusion. After ex vivo staining, fixation in 10% formalin, and tracing of the heart sections as described above, the central ischemic zones and the nonischemic zones of the three basal sections were dissected into epicardial, midmyocardial, and endocardial thirds. A gamma spectrometer (model 1185, Tracor, Inc., Austin, Tex.) was used to measure the radioactivity of the tissue and blood samples. An Apple 11+ computer was used to perform overlap corrections and myocardial blood flow calculations.
Protocol 2
Surgical preparation. During the course of the study, additional experiments were performed to determine the effects of oxypurinol or amflutizole on the formation and appearance of uric acid in coronary venous blood during reperfusion of the myocardium after a 90-minute period of regional ischemia.
As described above, dogs were anesthetized with Dial-urethane (0.6 ml/kg i.v.), and a left thoracotomy was performed. Dogs were treated with control solution (n=6), oxypurinol (n=4), or amflutizole (n=6) as described in protocol 1. The dogs treated with control solution or oxypurinol underwent occlusion of the left anterior descending coronary artery, and coronary venous blood was collected with a 7F Cournand catheter inserted in the right atrial appendage and advanced to the junction of the anterior interventricular vein and the great cardiac vein. The dogs treated with amflutizole underwent occlusion of the left circumflex coronary artery, and a vein draining the circumflex coronary artery bed was cannulated with an 18-gauge catheter for collection of coronary venous blood. Coronary artery occlusion was maintained for 90 minutes followed by reperfusion for 6 hours as in protocol 1.
Plasma uric acid. The blood samples for analysis of uric acid concentration were collected in heparinized tubes, were immediately placed on ice, and were then centrifuged at 0°C. The plasma was frozen at -700C until subsequent analysis. The concentration of uric acid was determined by high-pressure liquid chromatography as described previously. 16 Plasma amflutizole. Blood samples were obtained from seven dogs to measure the concentration of amflutizole. Nine milliliters of blood was mixed with 1 ml 3.8% sodium citrate. After centrifugation at 0°C, the plasma was stored at -70°C until subsequent analysis. The thawed samples were extracted 1:1 (vol/vol) with ethyl acetate containing 2% glacial acetic acid, mixed on a shaker (Eppendorf, Inc., Fremont, Calif.) for 5 minutes and centrifuged in a microfuge (Eppendorf) for Xanthine oxidase assay. The enzyme assay was performed at room temperature according to the procedure of Kalckar.'7 Xanthine oxidase activity was measured by the rate of uric acid formation from xanthine. In a total volume of 1.0 ml, the incubation mixture contained 50 ,umol potassium phosphate buffer, pH 7.4, 0.05 gmol xanthine, and 0.01 unit of the enzyme preparation (chromatographically purified milk xanthine oxidase, grade III, Sigma Chemical Co., St. Louis). The absorbance change at 292 nm was recorded by a recording spectrophotometer (Gilford), and the uric acid that was formed was calculated with an extinction coefficient of 12 mM/cm at 292 nm.
Statistics
All data are expressed as mean±SD. Differences were considered significant at a probability level less than 0.05. The preocclusion and postreperfusion uric acid concentrations were compared by a paired t test. Analysis of variance and Scheffe's multiple comparison confidence intervals were used to detect group differences in plasma uric acid, collateral blood flow, heart rate, mean arterial pressure, rate-pressure product (heart rate multiplied by mean arterial pressure), and area at risk in the left ventricle. Analysis of covariance, with the transmural regional myocardial blood flow as the covariate, was used to determine group differences in extent of infarct per area at risk. The incidence of fatal and nonfatal ventricular fibrillation among the three treatment groups was analyzed by the x2 test, but the sample sizes were insufficient to draw definitive conclusions.
Results

Survival
Sixteen animals did not satisfy the criteria for myocardial ischemia after coronary artery occlusion and were excluded from the designated protocol. Ventricular fibrillation occurred in 15 of the remaining 72 dogs: nine of 34 control dogs, three of 21 dogs that were treated with oxypurinol, and three of 17 dogs that were treated with amflutizole. Defibrillation was unsuccessful in four control dogs, one of which was treated with oxypurinol and three of which were treated with amflutizole. The incidence of fatal and nonfatal ventricular fibrillation was not significantly different among the three groups of dogs.
Extent of Myocardial Injury Figure 1 and Expressed as a percentage of the left ventricle, the extent of myocardial injury was 12±6% for the whole group of oxypurinol-treated dogs (n = 16) and 13 ± 6% for the subset with collateral blood flow data (n = 10). The extent of myocardial injury expressed as a percentage of the area at risk was 28±15% for the entire group of oxypurinol-treated dogs and 32±16% for the subset with collateral blood flow data.
Histological Examination
After 90 minutes of ischemia followed by 6 Figure 4 and summarized in Table 2 . Transcardiac gradients were not significantly different among the groups before coronary occlusion, whereas the gradients were significantly different after reperfusion (p<0.05). The transcardiac gradient of uric acid increased from a negative value to a positive value in four of the five control dogs; the mean gradient for the control group was -6.8±6. gM before occlusion and 17.4±26.6 ,uM after reperfusion. Eight of the nine drug-treated dogs had a negative transcardiac gradient of uric acid after reperfusion. Before occlusion, the mean gradient was 3.1±+ 12.7 ,M for the oxypurinol group and 1.8+5.9 ltM for the amflutizole group. After reperfusion, the mean gradient was -10.5 +5.8 ,uM for the oxypurinol group and -0.5±+ 1.3 gM for the amflutizole group.
Thus, the transcardiac gradients suggest that uric acid was released from the hearts of control dogs but not from the hearts of dogs that were treated with amflutizole or oxypurinol.
Inhibition of Xanthine Oxidase In Vitro
Amflutizole, compared with allopurinol, is a potent inhibitor of xanthine oxidase, with an '50 of 3.8 x 10-8 and 3 x 10-6M for amflutizole and allopurinol, respectively ( Figure 5 ). Kinetic studies indicated that inhibition by amflutizole was apparently noncompetitive with a Ki value of 1.24x 108M ( Figure 6 ). hours. Treatment with oxypurinol initiated at the same time point, however, did limit the extent of injury. There were no differences between the control and drug-treated groups with respect to heart rate, mean arterial pressure, or the rate-pressure product, suggesting that the smaller infarct size in the oxypurinol-treated group was not due to a lower myocardial oxygen demand. There were no significant differences in collateral blood flow among the dogs with regional myocardial blood flow data, indicating that the smaller infarct size in the oxypurinoltreated dogs was not due to a less-severe degree of regional ischemia. Renewed interest in the effects of xanthine oxidase inhibitors on ischemic myocardium was stimulated by the recognition that xanthine oxidase generates oxygen radicals and by the observation that free radical scavengers attenuated myocardial injury due to global and regional myocardial ischemia followed by reperfusion.' The xanthine oxidase activity of canine myocardium has been reported to increase during coronary artery occlusion,6 but there have been variable effects of xanthine oxidase inhibitors on canine myocardial injury due to regional ischemia (Table 3) .
Treatment with allopurinol beginning at least 1 day before coronary artery occlusion has been shown to limit the extent of canine myocardial injury after coronary occlusion for 606 or 909 minutes followed by reperfusion for 4 or 6 hours, respectively. Dogs treated with allopurinol for 48 hours before coronary artery occlusion have exhibited decreased myocardial stunning after regional ischemia for 15 minutes followed by reperfusion. 23 The beneficial effects of allopurinol have been attributed to alleviation of tissue injury during reperfusion, but further studies have found that pretreatment with allopurinol 24 hours before the onset of ischemia limited the extent of myocardial injury in dogs subjected to coronary artery occlusion for 24 hours without reperfusion. 24 The cardioprotective effects of allopurinol appear to depend on a period of long-term pretreatment 21 The results of other recent studies, however, indicate that short-term therapy with allopurinol may be sufficient to inhibit xanthine oxidase. Short-term administration of allopurinol has inhibited the formation of uric acid by rat hearts subjected to global ischemia and reperfusion. 16 Despite the evidence that both oxypurinol and amflutizole inhibited xanthine oxidase activity, only oxypurinol reduced the extent of myocardial injury. Thus, an unrecognized action of oxypurinol other than the inhibition of xanthine oxidase may account for oxypurinol's effect in this study and allopurinol's effect in previous studies. Based on in vitro data, previous studies suggest that oxypurinol acts as a scavenger of hydroxyl radicals2526 or of hypochlorous acid,27 an oxidant produced by activated neutrophils by the myeloperoxidase-catalyzed reaction involving hydrogen peroxide and chloride anion.28 Hypochlorous acid and its derivatives may potentiate tissue injury by inactivating a,-antiprotease, a protein that protects tissue elastin from hydrolysis by elastase.29 Hypochlorous acid also mediates the neutrophilinduced depletion of ATP in target cells.30 Oxypurinol, but not allopurinol, has prevented the inactivation of ac-antiprotease by hypochlorous acid. 27 The metabolism of allopurinol to oxypurinol is relatively slow; in dogs treated with allopurinol, the plasma concentration of oxypurinol has been shown to peak at 13 hours after injection of allopurinol.23 Thus, the lack of efficacy of the short-term dosing schedules of allopurinol used in previous studies10 may indicate that the plasma concentrations of oxypurinol achieved during the early phase of reperfusion were inadequate to counteract the cytotoxic actions of hypochlorous acid formed by neutrophils. The treatment of cats with allopurinol, however, did not enhance the capacity of plasma or lymph to scavenge hypochlorous acid or inhibit the peroxidation of lipids by hydrogen peroxide and myoglobin.31 Thus, the apparent cardioprotective effect of oxypurinol remains unexplained.
The cardioprotective effect of the oxypurinol regimen used in this study probably would not be sustained beyond reperfusion for 6 hours. Short-term administration of a drug may merely delay tissue injury because progressive myocardial damage occurs after reperfusion. For example, the infusion of iloprost, a stable analogue of prostacyclin, during coronary occlusion for 90 minutes and the first 2 hours of reperfusion was found to reduce infarct size after 6 hours32 but not 72 hours33 of reperfusion. The continuation of iloprost therapy until 48 hours after reperfusion did limit the extent of injury assessed 72 hours after reperfusion.33 Thus, it is not surprising that administration of oxypurinol before reperfusion failed to limit the ultimate extent of myocardial injury in dogs subjected to 40 or 90 minutes of coronary artery occlusion followed by reperfusion for 1 or 4 days. [34] [35] [36] Histochemical reagents such as triphenyltetrazolium chloride and nitro blue tetrazolium impart pigmentation to myocardium that retains the activities of dehydrogenase enzymes and their coenzymes,37 which may not be synonymous with cell viability. Nevertheless, the calculation of the extent of myocardial infarction using triphenyltetrazolium chloride or nitro blue tetrazolium correlates with the assessment of infarct size by electron microscopy,37 histopathology,38,39 the depletion of creatine kinase activity,40 the uptake of infarct-avid radionuclides,41,42 or antimyosin antibodies.43 According to Kloner et al,44 electron microscopic analysis of myocardium confirmed that triphenyltetrazolium chloride "... can reliably identify those areas of myocardium that demonstrate severe ultrastructural damage during the early phases of myocardial infarction, prior to the development of frank necrosis on histologic examination." Triphenyltetrazolium chloride and nitro blue tetrazolium may underestimate the size of small infarcts because of admixture of reversibly and irreversibly damaged tissue at the infarct border.38'45 Thus, the degree of myocardial salvage by pharmacological agents may be overestimated.
Collateral blood flow is an important determinant of the extent of canine myocardial injury during coronary artery occlusion.20 With collateral blood flow as a covariate, analysis of covariance demonstrated that the infarct size of the oxypurinol-treated dogs was significantly less than that of the control dogs. Although measurement of regional myocardial blood flow was not performed in every dog in this study, analysis of the infarct sizes of the dogs with collateral blood flow data yielded the same results as the analysis of the entire population of dogs. Therefore, the data support the conclusion that treatment with oxypurinol limited the extent of myocardial injury under the experimental conditions used in this study.
Studies reported by this46,47 and other laboratories19 imply that the primary phase of ischemic myocardial injury that is terminated by reperfusion may be followed by a secondary phase of tissue damage that can be alleviated by the administration at the time of reperfusion of agents that protect tissue from oxidants produced by neutrophils (extracellular) or other sources (intracellular). Currently, the beneficial effects of allopurinol and oxypurinol are interpreted as evidence supporting the hypothesis that reperfusion of ischemic tissue elicits injury caused by the xanthine oxidase reaction, which generates superoxide anions and hydrogen peroxide from molecular oxygen concomitant with the oxidation of xanthine and hypoxanthine.1 The present study suggests that the ability of oxypurinol and, perhaps, allopurinol to attenuate ischemic myocardial injury is unrelated to their inhibition of xanthine oxidase. Other laboratories also have obtained results that support the hypothesis that allopurinol's cardioprotective effect is not due to inhibition of xanthine oxidase. [48] [49] [50] Neither the pig nor the rabbit has been shown to have detectable xanthine oxidase activity.16,49-53 Nevertheless, the addition of either allopurinol or oxypurinol to the coronary perfusate has improved the contractility, compliance, and ATP concentration of pig hearts that were subjected to global ischemia followed by reperfusion.50 Treatment with allopurinol for 1 week has preserved the left ventricular function, the cellular and mitochondrial ATP concentrations, the ATPase activity of the sarcolemma and sarcoplasmic reticulum, and the myocardial ultrastructure of rabbit hearts that underwent coronary occlusion followed by reperfusion.4849 The administration of allopurinol to rabbits beginning 1 day before coronary artery occlusion has not altered the extent of myocardial injury as determined by the triphenyltetrazolium chloride method.52 The discordant effects of allopurinol on myocardial injury in the rabbit may relate to the different durations of treatment, the different experimental end points, or other unknown factors.
Extrapolation from the experimental data on xanthine oxidase to clinical therapeutics requires consideration of the existing knowledge about xanthine oxidase activity in human organs. Analysis of human liver and small intestine has revealed significant xanthine oxidase activity, although the activities were lower than those measured in other mammals. 54 Minimal xanthine oxidase activity was present in the human kidney.54 Although biochemical assays have not detected xanthine oxidase activity in homogenates of human myocardium,54-56 Jarasch et a157 observed immunohistochemical evidence of xanthine oxidase in the capillary endothelium of the human heart. Measurement of xanthine oxidase activity by chemiluminescence has indicated the presence of substantial xanthine oxidase activity in human umbilical vein endothelial cells.58 Human umbilical vein endothelial cells subjected to anoxia followed by reoxygenation have released superoxide anions.59 Treatment with superoxide dismutase plus catalase has attenuated the microvascular injury observed after transient occlusion of a canine coronary artery, suggesting that oxygen radicals are responsible for the endothelial injury associated with myocardial ischemia and reperfusion.60 Recently, Huizer et a161 studied the arteriovenous urate difference across the hearts of patients undergoing coronary angioplasty. Balloon inflation resulted in production of uric acid by the heart, suggesting that the human heart does contain active xanthine oxidoreductase activity. Thus, additional studies are needed to ascertain the mechanism of action of allopurinol and oxypurinol, and closer examination of the xanthine oxidase activity of cardiac endothelial cells is warranted to determine the importance of xanthine oxidase and other potential sources of oxygen radicals in the pathogenesis of postischemic myocardial injury.
